2型糖尿病与二甲双胍使用与NASH相关Child-Pugh A肝硬化患者结局相关
研究纳入299例活检证实的NASH合并Child-Pugh A肝硬化患者,中位随访5.1年,发现2型糖尿病与死亡、肝失代偿和HCC风险增加相关;二甲双胍使用与死亡或肝移植、肝失代偿和HCC风险降低相关,且部分获益仅在HbA1c>7.0%者中显著。
要点
- NASH相关Child-Pugh A肝硬化患者中,2型糖尿病增加死亡、肝失代偿和HCC风险。
- 二甲双胍使用与死亡或肝移植、肝失代偿和HCC风险降低相关。
- 二甲双胍对肝失代偿和HCC的显著降低仅见于HbA1c>7.0%的患者。
核心结论
- 在活检证实的NASH合并Child-Pugh A肝硬化患者中,2型糖尿病增加死亡和肝脏相关结局(包括HCC)风险,二甲双胍使用与生存率提高及肝失代偿和HCC风险降低相关。
研究设计与样本
- 国际多中心队列研究,纳入1995年4月至2016年12月西班牙、澳大利亚、香港和古巴三级医院299例活检证实的NASH合并Child-Pugh A肝硬化患者。
- 采用Cox比例风险和竞争风险模型估计无移植生存、肝失代偿和HCC的发生率。
主要发现
- 基线时212例患者有2型糖尿病,87例无糖尿病者中8例在中位随访5.1年(范围0.5-10.0年)期间发生糖尿病。
- 糖尿病患者的全随访期生存比例较低(38% vs 81%;aHR 4.23,95%CI 1.93-9.29)。
- 糖尿病患者肝失代偿比例较高(51% vs 26%;aHR 2.03,95%CI 1.005-4.11)。
- 糖尿病患者HCC比例较高(25% vs 7%;aHR 5.42,95%CI 1.74-16.80)。
- 随时间平均的HbA1c水平与结局无关;二甲双�胍使用与死亡或肝移植风险降低(aHR 0.41,95%CI 0.26-0.45)、肝失代偿风险降低(aHR 0.80,95%CI 0.74-0.97)和HCC风险降低(aHR 0.78,95%CI 0.69-0.96)相关。
关键数值与推荐
- 二甲双胍仅在HbA1c>7.0%的受试者中显著降低肝失代偿风险(aHR 0.97,95%CI 0.95-0.99)和HCC风险(aHR 0.67,95%CI 0.43-0.94)。
临床怎么用
- 对NASH相关Child-Pugh A肝硬化合并2型糖尿病患者,应积极管理糖尿病以降低死亡、肝失代偿和HCC风险。
- 二甲双胍使用可能与改善生存和降低肝失代偿及HCC风险相关,尤其在HbA1c>7.0%的患者中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Factors that affect outcomes of patients with nonalcoholic steatohepatitis (NASH)-related cirrhosis are unclear. We studied associations of type 2 diabetes, levels of hemoglobin A1c (HbA1c), and use of antidiabetic medications with survival and liver-related events in patients with NASH and compensated cirrhosis. METHODS: We collected data from 299 patients with biopsy-proven NASH with Child-Pugh A cirrhosis from tertiary hospitals in Spain, Australia, Hong Kong, and Cuba, from April 1995 through December 2016. We obtained information on the presence of type 2 diabetes, level of HbA1c, and use of antidiabetic medications. Cox proportional and competing risk models were used to estimate and compare rates of transplant-free survival, hepatic decompensation, and hepatocellular carcinoma (HCC). RESULTS: A total of 212 patients had type 2 diabetes at baseline and 8 of 87 patients developed diabetes during a median follow-up time of 5.1 years (range, 0.5-10.0 y). A lower proportion of patients with diabetes survived the entire follow-up period (38%) than of patients with no diabetes (81%) (adjusted hazard ratio [aHR], 4.23; 95% CI, 1.93-9.29). Higher proportions of patients with diabetes also had hepatic decompensation (51% vs 26% of patients with no diabetes; aHR, 2.03; 95% CI, 1.005-4.11) and HCC (25% vs 7% of patients with no diabetes; aHR, 5.42; 95% CI, 1.74-16.80). Averaged annual HbA1c levels over time were not associated with outcomes. Metformin use over time was associated with a significant reduction in risk of death or liver transplantation (aHR, 0.41; 95% CI, 0.26-0.45), hepatic decompensation (aHR, 0.80; 95% CI, 0.74-0.97), and HCC (aHR, 0.78; 95% CI, 0.69-0.96). Metformin significantly reduced the risk of hepatic decompensation and HCC only in subjects with HbA1c levels greater than 7.0% (aHR, 0.97; 95% CI, 0.95-0.99 and aHR, 0.67; 95% CI, 0.43-0.94, respectively). CONCLUSIONS: In an international cohort of patients with biopsy-proven NASH and Child-Pugh A cirrhosis, type 2 diabetes increased the risk of death and liver-related outcomes, including HCC. Patients who took metformin had higher rates of survival and lower rates of decompensation and HCC.
引用
- Vilar-Gomez E, Calzadilla-Bertot L, Wong VW, et al. Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. Clin Gastroenterol Hepatol. 2020. PMID: 32389886. doi:10.1016/j.cgh.2020.04.083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。